Skip to main content
SpringerLink
Log in
Book cover

Surgical Treatment for Advanced Heart Failure pp 9–34Cite as

Algorithm for Treatment of Advanced Heart Failure

  • Chapter
  • First Online:

  • 1415 Accesses

Abstract

Heart failure is a growing epidemic worldwide that confers a substantial medical and economic burden on our society. With the aging population and the improved treatment strategies made available over the last several decades including neurohormonal blockade, cardiac resynchronization, and multidisciplinary psychosocial interventions, the prevalence of advanced heart failure is increasing as patients with heart failure are living longer with parallel progression of their disease state. Judicious risk stratification and cautious patient selection are paramount in guiding appropriate therapies. It is imperative to understand the underlying pathophysiology, decision-making strategies, pharmacologic therapies, and comprehensive options in managing advanced heart failure. For patients who exhaust the widely available medical and surgical therapies, then additional algorithms and multidisciplinary decision teams must be in place for consideration of cardiac transplant or mechanical circulatory support device in this subcohort of advanced, end-stage heart failure.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Roger VL, Go AS, Lloyd-Jones DM, Benjamin EJ, Berry JD, Borden WB, et al. Heart disease and stroke statistics–2012 update: a report from the American Heart Association. Circulation. 2012;125(1):e2–220.

    Article  PubMed  Google Scholar 

  2. Lloyd-Jones D, Adams R, Carnethon M, De Simone G, Ferguson TB, Flegal K, et al. Heart disease and stroke statistics–2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2009;119(3):480–6.

    Article  PubMed  Google Scholar 

  3. Cappuccio FP. Commentary: epidemiological transition, migration, and cardiovascular disease. Int J Epidemiol. 2004;33(2):387–8.

    Article  PubMed  Google Scholar 

  4. Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, et al. ACC/AHA 2005 Guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (writing committee to update the 2001 guidelines for the evaluation and management of heart failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation. 2005;112(12):e154–235.

    Article  PubMed  Google Scholar 

  5. Deng MC, Naka Y. Circulatory support in advanced heart failure. Cardiol Rev. 2002;19:28–35.

    Google Scholar 

  6. Deng MC. The challenges of generating evidence to guide mechanical circulatory support-based management of advanced heart failure. Eur Heart J. 2005;26(10):953–5.

    Article  PubMed  Google Scholar 

  7. Jessup M, Brozena S. Heart failure. N Engl J Med. 2003;348(20):2007–18.

    Article  PubMed  Google Scholar 

  8. Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med. 2006;355(3):251–9.

    Article  PubMed  CAS  Google Scholar 

  9. Vasan RS, Larson MG, Benjamin EJ, Evans JC, Reiss CK, Levy D. Congestive heart failure in subjects with normal versus reduced left ventricular ejection fraction: prevalence and mortality in a population-based cohort. J Am Coll Cardiol. 1999;33(7):1948–55.

    Article  PubMed  CAS  Google Scholar 

  10. Gottdiener JS, McClelland RL, Marshall R, Shemanski L, Furberg CD, Kitzman DW, et al. Outcome of congestive heart failure in elderly persons: influence of left ventricular systolic function. The cardiovascular health study. Ann Intern Med. 2002;137(8):631–9.

    Article  PubMed  Google Scholar 

  11. Senni M, Tribouilloy CM, Rodeheffer RJ, Jacobsen SJ, Evans JM, Bailey KR, et al. Congestive heart failure in the community: a study of all incident cases in Olmsted County, Minnesota, in 1991. Circulation. 1998;98(21):2282–9.

    Article  PubMed  CAS  Google Scholar 

  12. Bhatia RS, Tu JV, Lee DS, Austin PC, Fang J, Haouzi A, et al. Outcome of heart failure with preserved ejection fraction in a population-based study. N Engl J Med. 2006;355(3):260–9.

    Article  PubMed  CAS  Google Scholar 

  13. Bramstedt KA, Nash PJ. When death is the outcome of informed refusal: dilemma of rejecting ventricular assist device therapy. J Heart Lung Transplant. 2005;24(2):229–30.

    Article  PubMed  Google Scholar 

  14. Hauptman PJ, Havranek EP. Integrating palliative care into heart failure care. Arch Intern Med. 2005;165(4):374–8.

    Article  PubMed  Google Scholar 

  15. Guyatt GH, Sullivan MJ, Thompson PJ, Fallen EL, Pugsley SO, Taylor DW, et al. The 6-minute walk: a new measure of exercise capacity in patients with chronic heart failure. Can Med Assoc J. 1985;132(8):919–23.

    PubMed  CAS  Google Scholar 

  16. Zugck C, Kruger C, Durr S, Gerber SH, Haunstetter A, Hornig K, et al. Is the 6-minute walk test a reliable substitute for peak oxygen uptake in patients with dilated cardiomyopathy? Eur Heart J. 2000;21(7):540–9.

    Article  PubMed  CAS  Google Scholar 

  17. Opasich C, Pinna GD, Mazza A, Febo O, Riccardi R, Riccardi PG, et al. Six-minute walking performance in patients with moderate-to-severe heart failure; is it a useful indicator in clinical practice? Eur Heart J. 2001;22(6):488–96.

    Article  PubMed  CAS  Google Scholar 

  18. Sharma R, Anker SD. The 6-minute walk test and prognosis in chronic heart failure–the available ­evidence. Eur Heart J. 2001;22(6):445–8.

    Article  PubMed  CAS  Google Scholar 

  19. Mancini DM, Eisen H, Kussmaul W, Mull R, Edmunds Jr LH, Wilson JR. Value of peak exercise oxygen consumption for optimal timing of cardiac transplantation in ambulatory patients with heart failure. Circulation. 1991;83(3):778–86.

    Article  PubMed  CAS  Google Scholar 

  20. Stevenson LW, Steimle AE, Fonarow G, Kermani M, Kermani D, Hamilton MA, et al. Improvement in exercise capacity of candidates awaiting heart transplantation. J Am Coll Cardiol. 1995;25(1):163–70.

    Article  PubMed  CAS  Google Scholar 

  21. Aaronson KD, Schwartz JS, Chen TM, Wong KL, Goin JE, Mancini DM. Development and prospective validation of a clinical index to predict survival in ambulatory patients referred for cardiac transplant evaluation. Circulation. 1997;95(12):2660–7.

    Article  PubMed  CAS  Google Scholar 

  22. Smits JM, Deng MC, Hummel M, De Meester J, Schoendube F, Scheld HH, et al. A prognostic model for predicting waiting-list mortality for a total national cohort of adult heart-transplant candidates. Transplantation. 2003;76(8):1185–9.

    Article  PubMed  Google Scholar 

  23. Lund LH, Aaronson KD, Mancini DM. Predicting survival in ambulatory patients with severe heart failure on beta-blocker therapy. Am J Cardiol. 2003;92(11):1350–4.

    Article  PubMed  Google Scholar 

  24. Levy WC, Mozaffarian D, Linker DT, Sutradhar SC, Anker SD, Cropp AB, et al. The Seattle Heart Failure Model: prediction of survival in heart failure. Circulation. 2006;113(11):1424–33.

    Article  PubMed  Google Scholar 

  25. Kalogeropoulos AP, Georgiopoulou VV, Giamouzis G, Smith AL, Agha SA, Waheed S, et al. Utility of the Seattle Heart Failure Model in patients with advanced heart failure. J Am Coll Cardiol. 2009;53(4):334–42.

    Article  PubMed  Google Scholar 

  26. Mehra MR, Jessup M, Gronda E, Costanzo MR. Rationale and process: International Society for Heart and Lung Transplantation guidelines for the care of cardiac transplant candidates–2006. J Heart Lung Transplant. 2006;25(9):1001–2.

    Article  PubMed  Google Scholar 

  27. Mann D. Heart failure: a companion to Braunwald’s heart disease: expert consult. 2nd ed. St. Louis: Saunders; 2010.

    Google Scholar 

  28. Petersen JW, Felker GM. Inotropes in the management of acute heart failure. Crit Care Med. 2008;36(1 Suppl):S106–11.

    Article  PubMed  CAS  Google Scholar 

  29. Parissis JT, Farmakis D, Nieminen M. Classical inotropes and new cardiac enhancers. Heart Fail Rev. 2007;12(2):149–56.

    Article  PubMed  Google Scholar 

  30. Feldman AM, Bristow MR, Parmley WW, Carson PE, Pepine CJ, Gilbert EM, et al. Effects of vesnarinone on morbidity and mortality in patients with heart failure. Vesnarinone Study Group. N Engl J Med. 1993 ;329(3):149–55.

    Article  PubMed  CAS  Google Scholar 

  31. The Xamoterol in Severe Heart Failure Study Group. Xamoterol in severe heart failure. Lancet. 1990;336(8706):1–6.

    Google Scholar 

  32. Cohn JN, Goldstein SO, Greenberg BH, Lorell BH, Bourge RC, Jaski BE, et al. A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure. Vesnarinone Trial Investigators. N Engl J Med. 1998;339(25):1810–6.

    Article  PubMed  CAS  Google Scholar 

  33. Hampton JR, van Veldhuisen DJ, Kleber FX, Cowley AJ, Ardia A, Block P, et al. Randomised study of effect of ibopamine on survival in patients with advanced severe heart failure. Second Prospective Randomised Study of Ibopamine on Mortality and Efficacy (PRIME II) Investigators. Lancet. 1997;349(9057):971–7.

    Article  PubMed  CAS  Google Scholar 

  34. Packer M, Carver JR, Rodeheffer RJ, Ivanhoe RJ, DiBianco R, Zeldis SM, et al. Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. N Engl J Med. 1991;325(21):1468–75.

    Article  PubMed  CAS  Google Scholar 

  35. Califf RM, Adams KF, McKenna WJ, Gheorghiade M, Uretsky BF, McNulty SE, et al. A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: the Flolan International Randomized Survival Trial (FIRST). Am Heart J. 1997;134(1):44–54.

    Article  PubMed  CAS  Google Scholar 

  36. Feldman AM, Oren RM, Abraham WT, Boehmer JP, Carson PE, Eichhorn E, et al. Low-dose oral enoximone enhances the ability to wean patients with ultra-advanced heart failure from intravenous inotropic support: results of the oral enoximone in intravenous inotrope-dependent subjects trial. Am Heart J. 2007;154(5):861–9.

    Article  PubMed  CAS  Google Scholar 

  37. Cleland JG, Daubert JC, Erdmann E, Freemantle N, Gras D, Kappenberger L, et al. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med. 2005;352(15):1539–49.

    Article  PubMed  CAS  Google Scholar 

  38. Mebazaa A, Nieminen MS, Packer M, Cohen-Solal A, Kleber FX, Pocock SJ, et al. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial. JAMA. 2007;297(17):1883–91.

    Article  PubMed  CAS  Google Scholar 

  39. Cleland JG, Freemantle N, Coletta AP, Clark AL. Clinical trials update from the American Heart Association: REPAIR-AMI, ASTAMI, JELIS, MEGA, REVIVE-II, SURVIVE, and PROACTIVE. Eur J Heart Fail. 2006;8(1):105–10.

    Article  PubMed  CAS  Google Scholar 

  40. Mills RM, LeJemtel TH, Horton DP, Liang C, Lang R, Silver MA, et al. Sustained hemodynamic effects of an infusion of nesiritide (human b-type natriuretic peptide) in heart failure: a randomized, double-blind, placebo-controlled clinical trial. Natrecor Study Group. J Am Coll Cardiol. 1999;34(1):155–62.

    Article  PubMed  CAS  Google Scholar 

  41. Sackner-Bernstein JD, Kowalski M, Fox M, Aaronson K. Short-term risk of death after treatment with nesiritide for decompensated heart failure: a pooled analysis of randomized controlled trials. JAMA. 2005;293(15):1900–5.

    Article  PubMed  CAS  Google Scholar 

  42. Colucci WS, Elkayam U, Horton DP, Abraham WT, Bourge RC, Johnson AD, et al. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. Nesiritide Study Group. N Engl J Med. 2000;343(4):246–53.

    Article  PubMed  CAS  Google Scholar 

  43. VMAC Investigators. Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial. JAMA. 2002;287(12):1531–40.

    Google Scholar 

  44. Peacock WF, Holland R, Gyarmathy R, Dunbar L, Klapholz M, Horton DP, et al. Observation unit treatment of heart failure with nesiritide: results from the proaction trial. J Emerg Med. 2005;29(3):243–52.

    Article  PubMed  Google Scholar 

  45. Dontas ID, Xanthos T, Dontas I, Lelovas P, Papadimitriou L. Impact of nesiritide on renal function and mortality in patients suffering from heart failure. Cardiovasc Drugs Ther. 2009;23(3):221–33.

    Article  PubMed  CAS  Google Scholar 

  46. Arora RR, Venkatesh PK, Molnar J. Short and long-term mortality with nesiritide. Am Heart J. 2006;152(6):1084–90.

    Article  PubMed  CAS  Google Scholar 

  47. O’Connor CM, Starling RC, Hernandez AF, Armstrong PW, Dickstein K, Hasselblad V, et al. Effect of nesiritide in patients with acute decompensated heart failure. N Engl J Med. 2011;365(1):32–43.

    Article  PubMed  Google Scholar 

  48. Udelson JE, Smith WB, Hendrix GH, Painchaud CA, Ghazzi M, Thomas I, et al. Acute hemodynamic effects of conivaptan, a dual V(1A) and V(2) vasopressin receptor antagonist, in patients with advanced heart failure. Circulation. 2001;104(20):2417–23.

    Article  PubMed  CAS  Google Scholar 

  49. Konstam MA, Gheorghiade M, Burnett Jr JC, Grinfeld L, Maggioni AP, Swedberg K, et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA. 2007;297(12):1319–31.

    Article  PubMed  CAS  Google Scholar 

  50. Garg R, Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials. JAMA. 1995;273(18):1450–6.

    Article  PubMed  CAS  Google Scholar 

  51. Wienbergen H, Schiele R, Gitt AK, Juenger C, Heer T, Meisenzahl C, et al. Impact of ramipril versus other angiotensin-converting enzyme inhibitors on outcome of unselected patients with ST-elevation acute myocardial infarction. Am J Cardiol. 2002;90(10):1045–9.

    Article  PubMed  CAS  Google Scholar 

  52. Giles TD, Katz R, Sullivan JM, Wolfson P, Haugland M, Kirlin P, et al. Short- and long-acting angiotensin-converting enzyme inhibitors: a randomized trial of lisinopril versus captopril in the treatment of congestive heart failure. The Multicenter Lisinopril-Captopril Congestive Heart Failure Study Group. J Am Coll Cardiol. 1989;13(6):1240–7.

    Article  PubMed  CAS  Google Scholar 

  53. Pilote L, Abrahamowicz M, Eisenberg M, Humphries K, Behlouli H, Tu JV. Effect of different angiotensin-converting-enzyme inhibitors on mortality among elderly patients with congestive heart failure. CMAJ. 2008;178(10):1303–11.

    Article  PubMed  Google Scholar 

  54. Vittorio TJ, Ahuja K, Kasper M, Turalic H, Tseng CH, Jorde UP, et al. Comparison of high- versus low-tissue affinity ACE-inhibitor treatment on circulating aldosterone levels in patients with chronic heart failure. J Renin Angiotensin Aldosterone Syst. 2007;8(4):200–4.

    Article  PubMed  CAS  Google Scholar 

  55. Nanas JN, Alexopoulos G, Anastasiou-Nana MI, Karidis K, Tirologos A, Zobolos S, et al. Outcome of patients with congestive heart failure treated with standard versus high doses of enalapril: a multicenter study. High Enalapril Dose Study Group. J Am Coll Cardiol. 2000;36(7):2090–5.

    Article  PubMed  CAS  Google Scholar 

  56. Swedberg K, Kjekshus J. Effects of enalapril on ­mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). Am J Cardiol. 1988;62(2):60A–6.

    Article  PubMed  CAS  Google Scholar 

  57. Swedberg K, Kjekshus J, Snapinn S. Long-term survival in severe heart failure in patients treated with enalapril. Ten year follow-up of CONSENSUS I. Eur Heart J. 1999;20(2):136–9.

    Article  PubMed  CAS  Google Scholar 

  58. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991;325(5):293–302.

    Google Scholar 

  59. Weber KT. Aldosterone in congestive heart failure. N Engl J Med. 2001;345(23):1689–97.

    Article  PubMed  CAS  Google Scholar 

  60. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al. The effect of spironolactone on ­morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341(10):709–17.

    Article  PubMed  CAS  Google Scholar 

  61. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348(14):1309–21.

    Article  PubMed  CAS  Google Scholar 

  62. Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011;364(1):11–21.

    Article  PubMed  CAS  Google Scholar 

  63. Cohn JN, Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med. 2001;345(23):1667–75.

    Article  PubMed  CAS  Google Scholar 

  64. Young JB, Dunlap ME, Pfeffer MA, Probstfield JL, Cohen-Solal A, Dietz R, et al. Mortality and morbidity reduction with Candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low-left ventricular ejection fraction trials. Circulation. 2004;110(17):2618–26.

    Article  PubMed  CAS  Google Scholar 

  65. Pitt B, Poole-Wilson PA, Segal R, Martinez FA, Dickstein K, Camm AJ, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial–the Losartan Heart Failure Survival Study ELITE II. Lancet. 2000;355(9215):1582–7.

    Article  PubMed  CAS  Google Scholar 

  66. Dickstein K, Kjekshus J. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. Lancet. 2002;360(9335):752–60.

    Article  PubMed  CAS  Google Scholar 

  67. Pfeffer MA, McMurray JJ, Velazquez EJ, Rouleau JL, Kober L, Maggioni AP, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med. 2003;349(20):1893–906.

    Article  PubMed  CAS  Google Scholar 

  68. McMurray JJ, Ostergren J, Swedberg K, Granger CB, Held P, Michelson EL, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking ­angiotensin-­converting-enzyme inhibitors: the CHARM-Added trial. Lancet. 2003;362(9386):767–71.

    Article  PubMed  CAS  Google Scholar 

  69. Dobre D, van Veldhuisen DJ, Goulder MA, Krum H, Willenheimer R. Clinical effects of initial 6 months monotherapy with bisoprolol versus enalapril in the treatment of patients with mild to moderate chronic heart failure. Data from the CIBIS III Trial. Cardiovasc Drugs Ther. 2008;22(5):399–405.

    Article  PubMed  CAS  Google Scholar 

  70. Remme WJ, Riegger G, Hildebrandt P, Komajda M, Jaarsma W, Bobbio M, et al. The benefits of early combination treatment of carvedilol and an ACE-inhibitor in mild heart failure and left ventricular systolic dysfunction. The carvedilol and ACE-inhibitor remodelling mild heart failure evaluation trial (CARMEN). Cardiovasc Drugs Ther. 2004;18(1):57–66.

    Article  PubMed  CAS  Google Scholar 

  71. Willenheimer R, van Veldhuisen DJ, Silke B, Erdmann E, Follath F, Krum H, et al. Effect on survival and hospitalization of initiating treatment for chronic heart failure with bisoprolol followed by enalapril, as compared with the opposite sequence: results of the randomized Cardiac Insufficiency Bisoprolol Study (CIBIS) III. Circulation. 2005;112(16):2426–35.

    Article  PubMed  CAS  Google Scholar 

  72. Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Effect of metoprolol CR/XL in chronic heart failure. Lancet. 1999;353(9169):2001–7.

    Google Scholar 

  73. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II). A randomised trial. Lancet. 1999;353(9146):9–13.

    Google Scholar 

  74. Packer M, Coats AJ, Fowler MB, Katus HA, Krum H, Mohacsi P, et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med. 2001;344(22):1651–8.

    Article  PubMed  CAS  Google Scholar 

  75. Poole-Wilson PA, Swedberg K, Cleland JG, Di Lenarda A, Hanrath P, Komajda M, et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet. 2003;362(9377):7–13.

    Article  PubMed  CAS  Google Scholar 

  76. Hjalmarson A, Waagstein F. COMET: a proposed mechanism of action to explain the results and concerns about dose. Lancet. 2003;362(9389):1077. author reply -8.

    Article  PubMed  Google Scholar 

  77. Cohn JN, Archibald DG, Ziesche S, Franciosa JA, Harston WE, Tristani FE, et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study. N Engl J Med. 1986;314(24):1547–52.

    Article  PubMed  CAS  Google Scholar 

  78. Cohn JN, Johnson G, Ziesche S, Cobb F, Francis G, Tristani F, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med. 1991;325(5):303–10.

    Article  PubMed  CAS  Google Scholar 

  79. Taylor AL, Ziesche S, Yancy C, Carson P, D’Agostino Jr R, Ferdinand K, et al. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med. 2004;351(20):2049–57.

    Article  PubMed  CAS  Google Scholar 

  80. Lewis GD, Shah R, Shahzad K, Camuso JM, Pappagianopoulos PP, Hung J, et al. Sildenafil improves exercise capacity and quality of life in patients with systolic heart failure and secondary pulmonary hypertension. Circulation. 2007;116(14):1555–62.

    Article  PubMed  CAS  Google Scholar 

  81. Narang R, Cleland JG, Erhardt L, Ball SG, Coats AJ, Cowley AJ, et al. Mode of death in chronic heart failure. A request and proposition for more accurate classification. Eur Heart J. 1996;17(9):1390–403.

    Article  PubMed  CAS  Google Scholar 

  82. Cleland JG, Erhardt L, Murray G, Hall AS, Ball SG. Effect of ramipril on morbidity and mode of death among survivors of acute myocardial infarction with clinical evidence of heart failure. A report from the AIRE Study Investigators. Eur Heart J. 1997;18(1):41–51.

    PubMed  CAS  Google Scholar 

  83. Doval HC, Nul DR, Grancelli HO, Perrone SV, Bortman GR, Curiel R. Randomised trial of low-dose amiodarone in severe congestive heart failure. Grupo de Estudio de la Sobrevida en la Insuficiencia Cardiaca en Argentina (GESICA). Lancet. 1994;344(8921):493–8.

    Article  PubMed  CAS  Google Scholar 

  84. Singh SN, Fletcher RD, Fisher SG, Singh BN, Lewis HD, Deedwania PC, et al. Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure. N Engl J Med. 1995;333(2):77–82.

    Article  PubMed  CAS  Google Scholar 

  85. Waldo AL, Camm AJ, deRuyter H, Friedman PL, MacNeil DJ, Pauls JF, et al. Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. The SWORD Investigators. Survival With Oral d-Sotalol. Lancet. 1996;348(9019):7–12.

    Article  PubMed  CAS  Google Scholar 

  86. Kober L, Torp-Pedersen C, McMurray JJ, Gotzsche O, Levy S, Crijns H, et al. Increased mortality after dronedarone therapy for severe heart failure. N Engl J Med. 2008;358(25):2678–87.

    Article  PubMed  Google Scholar 

  87. Kuck KH, Cappato R, Siebels J, Ruppel R. Randomized comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from cardiac arrest: the Cardiac Arrest Study Hamburg (CASH). Circulation. 2000;102(7):748–54.

    Article  PubMed  CAS  Google Scholar 

  88. Connolly SJ, Gent M, Roberts RS, Dorian P, Roy D, Sheldon RS, et al. Canadian implantable defibrillator study (CIDS): a randomized trial of the implantable cardioverter defibrillator against amiodarone. Circulation. 2000;101(11):1297–302.

    Article  PubMed  CAS  Google Scholar 

  89. The Antiarrhythmics versus Implantable Defibrillators (AVID) Investigators. A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. N Engl J Med. 1997;337(22):1576–83.

    Google Scholar 

  90. Epstein AE, DiMarco JP, Ellenbogen KA, Estes 3rd NA, Freedman RA, Gettes LS, et al. ACC/AHA/HRS 2008 Guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (writing committee to revise the ACC/AHA/NASPE 2002 Guideline update for implantation of cardiac pacemakers and antiarrhythmia devices) developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons. J Am Coll Cardiol. 2008;51(21):e1–62.

    Article  PubMed  Google Scholar 

  91. Moss AJ, Hall WJ, Cannom DS, Daubert JP, Higgins SL, Klein H, et al. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators. N Engl J Med. 1996;335(26):1933–40.

    Article  PubMed  CAS  Google Scholar 

  92. Buxton AE, Lee KL, Fisher JD, Josephson ME, Prystowsky EN, Hafley G. A randomized study of the prevention of sudden death in patients with coronary artery disease. Multicenter Unsustained Tachycardia Trial Investigators. N Engl J Med. 1999 ;341(25):1882–90.

    Article  PubMed  CAS  Google Scholar 

  93. Moss AJ, Zareba W, Hall WJ, Klein H, Wilber DJ, Cannom DS, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med. 2002;346(12):877–83.

    Article  PubMed  Google Scholar 

  94. Bardy GH, Lee KL, Mark DB, Poole JE, Packer DL, Boineau R, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med. 2005;352(3):225–37.

    Article  PubMed  CAS  Google Scholar 

  95. Grimm W, Christ M, Bach J, Muller HH, Maisch B. Noninvasive arrhythmia risk stratification in idiopathic dilated cardiomyopathy: results of the Marburg Cardiomyopathy Study. Circulation. 2003;108(23):2883–91.

    Article  PubMed  Google Scholar 

  96. Poole JE, Johnson GW, Hellkamp AS, Anderson J, Callans DJ, Raitt MH, et al. Prognostic importance of defibrillator shocks in patients with heart failure. N Engl J Med. 2008;359(10):1009–17.

    Article  PubMed  CAS  Google Scholar 

  97. Epstein AE, DiMarco JP, Ellenbogen KA, Estes 3rd NA, Freedman RA, Gettes LS, et al. ACC/AHA/HRS 2008 Guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (writing committee to revise the ACC/AHA/NASPE 2002 Guideline update for implantation of cardiac pacemakers and antiarrhythmia devices): developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons. Circulation. 2008;117(21):e350–408.

    Article  PubMed  Google Scholar 

  98. Cazeau S, Leclercq C, Lavergne T, Walker S, Varma C, Linde C, et al. Effects of multisite biventricular pacing in patients with heart failure and intraventricular conduction delay. N Engl J Med. 2001;344(12):873–80.

    Article  PubMed  CAS  Google Scholar 

  99. Abraham WT, Fisher WG, Smith AL, Delurgio DB, Leon AR, Loh E, et al. Cardiac resynchronization in chronic heart failure. N Engl J Med. 2002;346(24):1845–53.

    Article  PubMed  Google Scholar 

  100. Bristow MR, Saxon LA, Boehmer J, Krueger S, Kass DA, De Marco T, et al. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med. 2004;350(21):2140–50.

    Article  PubMed  CAS  Google Scholar 

  101. Cleland JG, Daubert JC, Erdmann E, Freemantle N, Gras D, Kappenberger L, et al. Longer-term effects of cardiac resynchronization therapy on mortality in heart failure [the CArdiac REsynchronization-Heart Failure (CARE-HF) trial extension phase]. Eur Heart J. 2006;27(16):1928–32.

    Article  PubMed  Google Scholar 

  102. Linde C, Abraham WT, Gold MR, St John Sutton M, Ghio S, Daubert C. Randomized trial of cardiac resynchronization in mildly symptomatic heart failure patients and in asymptomatic patients with left ventricular dysfunction and previous heart failure symptoms. J Am Coll Cardiol. 2008;52(23):1834–43.

    Article  PubMed  Google Scholar 

  103. Tang AS, Wells GA, Talajic M, Arnold MO, Sheldon R, Connolly S, et al. Cardiac-resynchronization therapy for mild-to-moderate heart failure. N Engl J Med. 2010;363(25):2385–95.

    Article  PubMed  CAS  Google Scholar 

  104. Moss AJ, Hall WJ, Cannom DS, Klein H, Brown MW, Daubert JP, et al. Cardiac-resynchronization therapy for the prevention of heart-failure events. N Engl J Med. 2009;361(14):1329–38.

    Article  PubMed  Google Scholar 

  105. Tracy CM, Epstein AE, Darbar D, Dimarco JP, Dunbar SB, Estes 3rd NA, et al. 2012 ACCF/AHA/HRS Focused update of the 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2012;126(14):1784–800.

    Article  PubMed  Google Scholar 

  106. Mullens W, Grimm RA, Verga T, Dresing T, Starling RC, Wilkoff BL, et al. Insights from a cardiac resynchronization optimization clinic as part of a heart failure disease management program. J Am Coll Cardiol. 2009;53(9):765–73.

    Article  PubMed  Google Scholar 

  107. Cleland JG, Calvert MJ, Verboven Y, Freemantle N. Effects of cardiac resynchronization therapy on long-term quality of life: an analysis from the CArdiac Resynchronisation-Heart Failure (CARE-HF) study. Am Heart J. 2009;157(3):457–66.

    Article  PubMed  Google Scholar 

  108. Donahue T, Niazi I, Leon A, Stucky M, Herrmann K. Acute and chronic response to CRT in narrow QRS patients. J Cardiovasc Transl Res. 2012;5(2):232–41.

    Article  PubMed  Google Scholar 

  109. Beshai JF, Grimm RA, Nagueh SF, Baker 2nd JH, Beau SL, Greenberg SM, et al. Cardiac-resynchronization therapy in heart failure with narrow QRS complexes. N Engl J Med. 2007;357(24):2461–71.

    Article  PubMed  CAS  Google Scholar 

  110. Yu CM, Wing-Hong Fung J, Zhang Q, Sanderson JE. Understanding nonresponders of cardiac resynchronization therapy–current and future perspectives. J Cardiovasc Electrophysiol. 2005;16(10):1117–24.

    Article  PubMed  Google Scholar 

  111. Beshai JF, Khunnawat C, Lin AC. Mechanical dyssynchrony from the perspective of a cardiac electrophysiologist. Curr Opin Cardiol. 2008;23(5):447–51.

    Article  PubMed  Google Scholar 

  112. Winkel E, Piccione W. Coronary artery bypass surgery in patients with left ventricular dysfunction: candidate selection and perioperative care. J Heart Lung Transplant. 1997;16(6):S19–24.

    PubMed  CAS  Google Scholar 

  113. Di Carli MF, Asgarzadie F, Schelbert HR, Brunken RC, Laks H, Phelps ME, et al. Quantitative relation between myocardial viability and improvement in heart failure symptoms after revascularization in patients with ischemic cardiomyopathy. Circulation. 1995;92(12):3436–44.

    Article  PubMed  Google Scholar 

  114. Hausmann H, Topp H, Siniawski H, Holz S, Hetzer R. Decision-making in end-stage coronary artery disease: revascularization or heart transplantation? Ann Thorac Surg. 1997;64(5):1296–301. discussion 302.

    Article  PubMed  CAS  Google Scholar 

  115. Elefteriades JA, Tolis Jr G, Levi E, Mills LK, Zaret BL. Coronary artery bypass grafting in severe left ventricular dysfunction: excellent survival with improved ejection fraction and functional state. J Am Coll Cardiol. 1993;22(5):1411–7.

    Article  PubMed  CAS  Google Scholar 

  116. Olsen PS, Kassis E, Niebuhr-Jorgensen U. Coronary artery bypass surgery in patients with severe left-ventricular dysfunction. Thorac Cardiovasc Surg. 1993;41(2):118–20.

    Article  PubMed  CAS  Google Scholar 

  117. Mickleborough LL, Maruyama H, Takagi Y, Mohamed S, Sun Z, Ebisuzaki L. Results of revascularization in patients with severe left ventricular dysfunction. Circulation. 1995;92(9 Suppl):II73–9.

    PubMed  CAS  Google Scholar 

  118. Joyce D, Loebe M, Noon GP, McRee S, Southard R, Thompson L, et al. Revascularization and ventricular restoration in patients with ischemic heart failure: the STICH trial. Curr Opin Cardiol. 2003;18(6):454–7.

    Article  PubMed  Google Scholar 

  119. Veenhuyzen GD, Singh SN, McAreavey D, Shelton BJ, Exner DV. Prior coronary artery bypass surgery and risk of death among patients with ischemic left ventricular dysfunction. Circulation. 2001;104(13):1489–93.

    Article  PubMed  CAS  Google Scholar 

  120. Alderman EL, Bourassa MG, Cohen LS, Davis KB, Kaiser GG, Killip T, et al. Ten-year follow-up of survival and myocardial infarction in the randomized Coronary Artery Surgery Study. Circulation. 1990;82(5):1629–46.

    Article  PubMed  CAS  Google Scholar 

  121. The VA Coronary Artery Bypass Surgery Cooperative Study Group. Eighteen-year follow-up in the Veterans Affairs Cooperative Study of Coronary Artery Bypass Surgery for stable angina. Circulation. 1992;86(1):121–30.

    Google Scholar 

  122. Velazquez EJ, Lee KL, Deja MA, Jain A, Sopko G, Marchenko A, et al. Coronary-artery bypass surgery in patients with left ventricular dysfunction. N Engl J Med. 2011;364(17):1607–16.

    Article  PubMed  CAS  Google Scholar 

  123. Rahimtoola SH. Concept and evaluation of hibernating myocardium. Annu Rev Med. 1999;50:75–86.

    Article  PubMed  CAS  Google Scholar 

  124. Nicolini F, Gherli T. Alternatives to transplantation in the surgical therapy for heart failure. Eur J Cardiothorac Surg. 2009;35(2):214–28.

    Article  PubMed  Google Scholar 

  125. Dreyfus G, Duboc D, Blasco A, Dubois C, Brodaty D, Chatel D, et al. Coronary surgery can be an alternative to heart transplantation in selected patients with end-stage ischemic heart disease. Eur J Cardiothorac Surg. 1993;7(9):482–7. discussion 8.

    Article  PubMed  CAS  Google Scholar 

  126. Kron IL. When does one replace the heart in ischemic cardiomyopathy? Ann Thorac Surg. 1993;55(3):581.

    Article  PubMed  CAS  Google Scholar 

  127. Lansman SL, Ergin MA, Griepp RB. The history of heart and heart-lung transplantation. Cardiovasc Clin. 1990;20(2):3–19.

    PubMed  CAS  Google Scholar 

  128. Tjan TD, Kondruweit M, Scheld HH, Roeder N, Borggrefe M, Schmidt C, et al. The bad ventricle–revascularization versus transplantation. Thorac Cardiovasc Surg. 2000;48(1):9–14.

    Article  PubMed  CAS  Google Scholar 

  129. Bonow RO, Maurer G, Lee KL, Holly TA, Binkley PF, Desvigne-Nickens P, et al. Myocardial viability and survival in ischemic left ventricular dysfunction. N Engl J Med. 2011;364(17):1617–25.

    Article  PubMed  CAS  Google Scholar 

  130. Bolling SF, Pagani FD, Deeb GM, Bach DS. Intermediate-term outcome of mitral reconstruction in cardiomyopathy. J Thorac Cardiovasc Surg. 1998;115(2):381–6. discussion 7-8.

    Article  PubMed  CAS  Google Scholar 

  131. Rukosujew A, Klotz S, Welp H, Bruch C, Ghezelbash F, Schmidt C, et al. Surgery of secondary mitral insufficiency in patients with impaired left ventricular function. J Cardiothorac Surg. 2009;4:36.

    Article  PubMed  Google Scholar 

  132. Athanasuleas CL, Stanley Jr AW, Buckberg GD, Dor V, DiDonato M, Blackstone EH. Surgical anterior ventricular endocardial restoration (SAVER) in the dilated remodeled ventricle after anterior myocardial infarction. RESTORE group. Reconstructive Endoventricular Surgery, returning Torsion Original Radius Elliptical Shape to the LV. J Am Coll Cardiol. 2001;37(5):1199–209.

    Article  PubMed  CAS  Google Scholar 

  133. McCarthy JF, McCarthy PM, Starling RC, Smedira NG, Scalia GM, Wong J, et al. Partial left ventriculectomy and mitral valve repair for end-stage congestive heart failure. Eur J Cardiothorac Surg. 1998;13(4):337–43.

    Article  PubMed  CAS  Google Scholar 

  134. Athanasuleas CL, Buckberg GD, Stanley AW, Siler W, Dor V, Di Donato M, et al. Surgical ventricular restoration in the treatment of congestive heart failure due to post-infarction ventricular dilation. J Am Coll Cardiol. 2004;44(7):1439–45.

    Article  PubMed  Google Scholar 

  135. Jones RH, Velazquez EJ, Michler RE, Sopko G, Oh JK, O’Connor CM, et al. Coronary bypass surgery with or without surgical ventricular reconstruction. N Engl J Med. 2009;360(17):1705–17.

    Article  PubMed  CAS  Google Scholar 

  136. Allen LA, Stevenson LW, Grady KL, Goldstein NE, Matlock DD, Arnold RM, et al. Decision making in advanced heart failure: a scientific statement from the American Heart Association. Circulation. 2012;125(15):1928–52.

    Article  PubMed  Google Scholar 

  137. Crespo-Leiro MG, Barge-Caballero E, Marzoa-Rivas R, Paniagua-Martin MJ. Heart transplantation. Curr Opin Organ Transplant. 2010;15(5):633–8.

    Article  PubMed  Google Scholar 

  138. McMurray JJ, Pfeffer MA. Heart failure. Lancet. 2005;365(9474):1877–89.

    Article  PubMed  Google Scholar 

  139. Nieminen MS, Bohm M, Cowie MR, Drexler H, Filippatos GS, Jondeau G, et al. Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: the Task Force on Acute Heart Failure of the European Society of Cardiology. Eur Heart J. 2005;26(4):384–416.

    Article  PubMed  Google Scholar 

  140. Feldman D, Pamboukian SV, Teuteberg JJ, Birks E, Lietz K, Moore SA, et al. The 2013 International Society for Heart and Lung Transplantation Guidelines for mechanical circulatory support: executive summary. J Heart Lung Transplant. 2013:32(2):157–87.

    Article  PubMed  CAS  Google Scholar 

  141. Rose EA, Gelijns AC, Moskowitz AJ, Heitjan DF, Stevenson LW, Dembitsky W, et al. Long-term use of a left ventricular assist device for end-stage heart failure. N Engl J Med. 2001;345(20):1435–43.

    Article  PubMed  CAS  Google Scholar 

  142. Wilson SR, Mudge Jr GH, Stewart GC, Givertz MM. Evaluation for a ventricular assist device: selecting the appropriate candidate. Circulation. 2009;119(16):2225–32.

    Article  PubMed  Google Scholar 

  143. Miller LW, Pagani FD, Russell SD, John R, Boyle AJ, Aaronson KD, et al. Use of a continuous-flow device in patients awaiting heart transplantation. N Engl J Med. 2007;357(9):885–96.

    Article  PubMed  CAS  Google Scholar 

  144. Slaughter MS, Rogers JG, Milano CA, Russell SD, Conte JV, Feldman D, et al. Advanced heart failure treated with continuous-flow left ventricular assist device. N Engl J Med. 2009;361(23):2241–51.

    Article  PubMed  CAS  Google Scholar 

  145. Copeland JG, Smith RG, Arabia FA, Nolan PE, Sethi GK, Tsau PH, et al. Cardiac replacement with a total artificial heart as a bridge to transplantation. N Engl J Med. 2004;351(9):859–67.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Cardiology, David Geffen School of Medicine, Ronald Reagan UCLA Medical Center, 100 UCLA Medical Plaza, Suite 630 East, Los Angeles, CA, 90095, USA

    Richard K. Cheng M.D., Mrudula R. Allareddy M.D., Eugene C. DePasquale M.D. & Mario C. Deng M.D., FAAC, FESC

  2. Division of Cardiology, Department of Medicine, New York-Presbyterian Hospital, 622 West 168th Street, New York, NY, 10032, USA

    Farhana Latif M.D. & Khurram Shahzad M.D., M.S.

Authors
  1. Richard K. Cheng M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mrudula R. Allareddy M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Eugene C. DePasquale M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Farhana Latif M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Khurram Shahzad M.D., M.S.
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Mario C. Deng M.D., FAAC, FESC
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Richard K. Cheng M.D. .

Editor information

Editors and Affiliations

  1. Division of Cardiothoracic Surgery, Henry Ford Hospital, West Grand Blvd. 2799, Detroit, 48202, Michigan, USA

    Jeffrey A. Morgan

  2. Department of Cardiothoracic Surgery, New York Presbyterian Hospital, Fort Washington Avenue 177, New York, 10032, New York, USA

    Yoshifumi Naka

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer Science+Business Media New York

About this chapter

Cite this chapter

Cheng, R.K., Allareddy, M.R., DePasquale, E.C., Latif, F., Shahzad, K., Deng, M.C. (2013). Algorithm for Treatment of Advanced Heart Failure. In: Morgan, J., Naka, Y. (eds) Surgical Treatment for Advanced Heart Failure. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-6919-3_2

Download citation

  • DOI: https://doi.org/10.1007/978-1-4614-6919-3_2

  • Published:

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4614-6918-6

  • Online ISBN: 978-1-4614-6919-3

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation